News briefing: Gyroscope and Talaris set IPO terms; FDA grants expanded nod to Chiesi's sickle cell drug
In a week where two biotech IPOs were already expected, another two prospective entrants have set their debut terms ahead of their launch later this week.
Gyroscope Therapeutics and Talaris Therapeutics each set IPO terms Monday morning. Gyroscope, based out of the UK, is planning to offer 6.8 million ADSs at a price range of $20 to $22, while Talaris expects to offer 8.8 million shares between $16 and $18 each.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.